High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs

被引：0
|
作者：
Takahisa Kawamura
Akito Hata
Jumpei Takeshita
Shiro Fujita
Michio Hayashi
Keisuke Tomii
Nobuyuki Katakami
机构：
[1] Kobe City Medical Center General Hospital,Department of Respiratory Medicine
[2] Institute of Biomedical Research and Innovation,Division of Integrated Oncology
来源：
Cancer Chemotherapy and Pharmacology | 2015年 / 75卷
关键词：
Non-small cell lung cancer; EGFR-TKI; Leptomeningeal metastases; High-dose erlotinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1261 / 1266
页数：5
相关论文
共 16 条
  • [1] High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs
    Kawamura, Takahisa
    Hata, Akito
    Takeshita, Jumpei
    Fujita, Shiro
    Hayashi, Michio
    Tomii, Keisuke
    Katakami, Nobuyuki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (06) : 1261 - 1266
  • [2] Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer
    Nanjo, Shigeki
    Hata, Akito
    Okuda, Chiyuki
    Kaji, Reiko
    Okada, Hideaki
    Tamura, Daisuke
    Irie, Kei
    Okada, Hiroshi
    Fukushima, Shoji
    Katakami, Nobuyuki
    BRITISH JOURNAL OF CANCER, 2018, 118 (01) : 32 - 37
  • [3] Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer
    Shigeki Nanjo
    Akito Hata
    Chiyuki Okuda
    Reiko Kaji
    Hideaki Okada
    Daisuke Tamura
    Kei Irie
    Hiroshi Okada
    Shoji Fukushima
    Nobuyuki Katakami
    British Journal of Cancer, 2018, 118 : 32 - 37
  • [4] High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases-One with a remarkable thoracic response as well
    Kuiper, J. L.
    Smit, E. F.
    LUNG CANCER, 2013, 80 (01) : 102 - 105
  • [5] Dramatic response to high-dose icotinib in a lung adenocarcinoma patient after erlotinib failure
    Guan, Yin
    Zhao, Hong
    Meng, Jing
    Yan, Xiang
    Jiao, ShunChang
    LUNG CANCER, 2014, 83 (02) : 305 - 307
  • [6] High-dose Erlotinib for Refractory Brain Metastases in a Patient with Relapsed Non-small Cell Lung Cancer
    Hata, Akito
    Kaji, Reiko
    Fujita, Shiro
    Katakami, Nobuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (03) : 653 - 654
  • [7] High-Dose Furmonertinib in Patients With EGFR-Mutated NSCLC and Leptomeningeal Metastases: A Prospective Real-World Study
    Chen, Haiyang
    Yang, Sen
    Wang, Lili
    Wu, Yingxi
    Wu, Yufeng
    Ma, Shuxiang
    He, Zhen
    Zhang, Cuicui
    Liu, Yang
    Tang, Haoran
    Dong, Hang
    Wang, Qiming
    JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (01) : 65 - 75
  • [8] "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer
    Grommes, Christian
    Oxnard, Geoffrey R.
    Kris, Mark G.
    Miller, Vincent A.
    Pao, William
    Holodny, Andrei I.
    Clarke, Jennifer L.
    Lassman, Andrew B.
    NEURO-ONCOLOGY, 2011, 13 (12) : 1364 - 1369
  • [9] High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib
    Kuiper, J. L.
    Heideman, D. A. M.
    Thunnissen, E.
    van Wijk, A. W.
    Postmus, P. E.
    Smit, E. F.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (07) : 1399 - 1401
  • [10] Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
    Ying Yuan
    Chunwen Tan
    Modan Li
    Hong Shen
    Xuefeng Fang
    Yinghong Hu
    Shenglin Ma
    World Journal of Surgical Oncology, 10
12